TTrialPathMatch Me to Trials
← Back to trials
RecruitingDiabetes Mellitus, Type 2

Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes

Eligible age

30–80 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.

Sponsor: Hospital de Clinicas de Porto Alegre

You may qualify if…

  • ✓ Female and male individuals, with clinical diagnosis of DM2 for at least 6 months;
  • ✓ Age over 30 years;
  • ✓ BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months;
  • ✓ HbA1c between 7.5% and 10.5%.

You may not qualify if…

  • ✕ Use of herbal supplements, antioxidants, and multivitamins in the last 3 months;
  • ✕ Pregnancy or lactation;
  • ✕ Chronic renal failure with glomerular filtration rate calculated by MDRD \< 30 mL/h;
  • ✕ Myocardial infarction in the last than 6 months
  • ✕ Current neoplasia;
  • ✕ Chronic use of glucocorticoids;
  • ✕ Bariatric surgery.

Source: ClinicalTrials.gov · NCT04874012 · last updated 2026-09-24

Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Indivi · TrialPath